10/18/21 6:09 PMNasdaq : LUCD, PAVM, PAVMZIPOofferingLucid Diagnostics Announces Closing of Nasdaq Initial Public OfferingLucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc., today announced the closing on October 18, 2021 of its initial public offering of 5,000,000 shares of common stock at a price to the public of $14.00 per share for total gross proceeds of $70,000,000 before deducting underwriting...RHEA-AIneutral
10/18/21 5:45 PMNasdaq : LUCDIPOofferingLucid Diagnostics Announces Closing of Nasdaq Initial Public OfferingLucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the closing on October 18, 2021 of its initial publicRHEA-AIneutral
10/13/21 10:15 PMNasdaq : LUCDIPOofferingLucid Diagnostics Announces Pricing of Initial Public OfferingLucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the pricing of its initial public offering of 5,000,000RHEA-AIneutral
10/13/21 9:28 PMNasdaq : PAVM, LUCD, PAVMZIPOofferingLucid Diagnostics Announces Pricing of Initial Public OfferingLucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc., today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share. Lucid's common stock is expected to begin trading on The Nasdaq Stock Market under the ticker...RHEA-AIneutral
